In this interview with Prepared Foods, Eyal Rosenthal, CEO of Ever After Foods, Ltd., discusses the company’s advancements in cell-based meat production. Learn how Ever After's technology eschewed the industry standard and is able to produce a high volume, so-far comparatively low cost product.
The $999,967 two-year grant is a testament to Novel Farms' work in the field of cultivated meat production and will provide critical funding to support the scale-up of their proprietary scaffolding platform.
Company promotes senior vice president of R&D to chief scientific officer and appoints former Twitter executive as chief legal officer
August 8, 2023
These strategic appointments underscore UPSIDE's dedication to assembling an exceptional industry-defining leadership team to drive the company's growth in its next phase.
Company begins production and prepares for launch with restaurateur José Andrés
June 23, 2023
The moment for the burgeoning cultivated meat, poultry and seafood sector, and for the global food industry, comes on the heels of the USDA’s approval of GOOD Meat’s label – and four months after the company received its “no questions” letter from the US Food and Drug Administration.
The milestone moves the company a step closer to commercialization
June 15, 2023
With an approved label in hand, UPSIDE Foods is now working with USDA to obtain a Grant of Inspection (GOI) for its Engineering, Production, and Innovation Center (EPIC), the last remaining item in the pre-market regulatory process before the company can commercially produce and sell its cultivated chicken in the United States.
Alternative proteins, which include cultivated, plant-based, and fermentation-derived proteins, represent an opportunity to reduce risks and improve the efficiency of meat production, while offering consumers the meat-eating experience they crave. Rethinking how meat is made can decrease emissions, protect human health, ensure food security for all, and maintain and improve biodiversity. Good Food Institute
is calling on governments around the world to invest $10 billion each year in R&D and commercialization to deliver the full benefits of protein diversification.
Industry focus has been on technological and industrial applications of alternative proteins, but it is the understanding of safety aspects that will be the key to long-term success.
UPSIDE made history last year with its landmark FDA "green light" for its whole-textured chicken
May 3, 2023
UPSIDE announced that it has developed a breakthrough chicken cell line for use in suspension cell culture that could substantially reduce the cost of production for these ground meat products.